ARSEUS |
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| 13/05 | Fagron NV Approves Dividend for the Year 2023, Payable on 23 May 2024 | CI |
| 11/04 | Transcript : Fagron NV, Q1 2024 Sales/ Trading Statement Call, Apr 11, 2024 |
| Sales 2024 * | 84Cr 90Cr 7.51TCr | Sales 2025 * | 90Cr 96Cr 8TCr | Capitalization | 132.98Cr 142.44Cr 12TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 8.2Cr 8.78Cr 732.42Cr | Net income 2025 * | 9.6Cr 10Cr 857.46Cr | EV / Sales 2024 * | 1.85 x |
| Net Debt 2024 * | 23Cr 24Cr 2.04TCr | Net Debt 2025 * | 18Cr 19Cr 1.58TCr | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 * |
16.2
x | P/E ratio 2025 * |
14.1
x | Employees | - |
| Yield 2024 * |
1.6% | Yield 2025 * |
1.75% | Free-Float | 94.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on ARSEUS
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 27/17/27 | |
Karin de Jong
DFI | Director of Finance/CFO | 45 | 01/08/01 |
Vera Bakker
COO | Chief Operating Officer | 52 | 09/22/09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Koen Hoffman
CHM | Chairman | 56 | 01/16/01 |
| Director/Board Member | 64 | 01/19/01 | |
| Chief Executive Officer | 46 | 27/17/27 |
Fagron N.V. specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The group ensures the sale of pharmaceutical formulas and raw materials, provides third-party pharmaceutical compounding services to pharmacists and hospitals, etc.
Sector
Pharmaceuticals
Calendar
01/08/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 82TCr | |
| +44.05% | 64TCr | |
| -6.75% | 35TCr | |
| +13.56% | 31TCr | |
| +10.68% | 30TCr | |
| +16.57% | 24TCr | |
| +13.31% | 22TCr | |
| +8.48% | 17TCr | |
| -2.81% | 16TCr |
